MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,947K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation
Sale of common stock for cash
Accounts payable and accrued lia...
Others
Negative Cash Flow Breakdown
Research and development tax cre...
Net loss
Purchase of equipment
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-1,273
-5,407
-5,264
-6,472
Stock-based compensation
1,358
1,497
3,316
2,984
Accretion of debt discount
-
-
0
-
Gain on settlement of accounts payable
0
-91
-1,252
626
Depreciation expense
66
52
56
28
Impairment of acquired in-process research and development intangible assets
-
-
0
0
Research and development tax credit receivable
3,934
-3,805
2,580
99
Other tax receivable
63
34
-503
210
Prepaid expenses
-73
99
123
-33
Prepaid expenses related party
-
-
0
-
Other assets
-146
88
-151
176
Accounts payable and accrued liabilities
394
-3,018
893
-170
Deferred liabilities
-
-
0
-511
Operating lease liabilities
58
-20
104
-61
Net cash used in operating activities
-3,175
-3,403
-2,944
-5,439
Purchase of fixed assets
-
-
143
193
Purchase of equipment
430
-
-
-
Net cash used in investing activities
-430
-
-143
-193
Sale of common stock for cash
584
-
0
0
Cash proceeds for amendment of warrants
-
-
67
-
Exercise of warrants for cash
130
-
0
0
Exercise of stock options for cash
35
-
-
-
Net cash provided by financing activities
749
-
67
0
Impact on cash from foreign currency translation
-91
10
37
-8
Net (decrease) increase in cash and cash equivalents
-2,947
-3,393
-2,983
-5,640
Cash and cash equivalents at beginning of period
21,358
24,751
27,734
20,922
Cash and cash equivalents at end of period
18,411
21,358
24,751
27,734
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sale of common stock
for cash
$584K
(-97.88%↓ Y/Y)
Exercise of warrants for
cash
$130K
(12900.00%↑ Y/Y)
Exercise of stock options
for cash
$35K
Net cash provided by
financing activities
$749K
(-97.28%↓ Y/Y)
Net (decrease)
increase in cash and cash...
-$2,947K
(-123.67%↓ Y/Y)
Canceled cashflow
$749K
Stock-based compensation
$1,358K
(-62.38%↓ Y/Y)
Accounts payable and
accrued liabilities
$394K
(-65.19%↓ Y/Y)
Other assets
-$146K
(-129.74%↓ Y/Y)
Prepaid expenses
-$73K
(-141.95%↓ Y/Y)
Depreciation expense
$66K
Operating lease
liabilities
$58K
Net cash used in
operating activities
-$3,175K
(77.64%↑ Y/Y)
Canceled cashflow
$2,095K
Net cash used in
investing activities
-$430K
(39.09%↑ Y/Y)
Impact on cash from
foreign currency...
-$91K
(51.60%↑ Y/Y)
Research and development
tax credit...
$3,934K
(827.83%↑ Y/Y)
Net loss
-$1,273K
(96.28%↑ Y/Y)
Other tax receivable
$63K
(-80.43%↓ Y/Y)
Purchase of equipment
$430K
(-39.09%↓ Y/Y)
Buy us a coffee
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)